基於整體試驗最終數據下，印度批准強生新冠疫苗緊急使用授權-To The Moon - Tiger Brokers Online Investing Community - To The Moon

8
5
Favorite

基於整體試驗最終數據下，印度批准強生新冠疫苗緊急使用授權

美股研究社
2021-08-09

強生的單劑疫苗是繼阿斯利康(AZN.US)、Bharat Biotech、俄羅斯Gamaleya和Moderna(MRNA.US)之後在印度獲得監管授權的第五種新冠疫苗。

美股研究社獲悉，據智通財經APP消息，印度衛生部部長Mansukh Mandaviya於上週六在其推特上表示，印度已批准$強生(JNJ)$ 研發的新冠疫苗的緊急使用授權。

據悉，該批准是基於3期整體臨牀試驗的最終數據。強生已經與當地疫苗生產商Biological E Ltd簽署了供應協議，但具體的時間表尚未透露。

有媒體援引強生公司的聲明表示:“雖然我們期待着兌現我們的交付承諾，但現在透露交付疫苗的具體時間還爲時過早。”

據瞭解，在7月底，有媒體報道，強生的新冠疫苗對德爾塔變異病毒仍具有大約71%的有效性。

根據約翰霍普金斯大學的統計數據，印度的新冠病毒感染人數在全球排第二，但該國只有約8%的人口完成了全面疫苗接種。

本文來源：美股研究社，旨在幫助中國投資者理解世界，專注報道美國科技股和中概股，對美股感興趣的朋友趕緊關注我們

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

8

Report

Comment（5）

Top
Latest

nyf
·2021-08-09
Good
Reply
1
Report
Ivylow
·2021-08-09
?
Reply
1
Report
keithsk
·2021-08-09
[Smile]
Reply
1
Report
Jacobkoo
·2021-08-09
Good
Reply
2
Report
Dino23
·2021-08-09
?
Reply
2
Report

Most Discussed

Terms and Conditions·Privacy Policy

Company: TTMF Limited. Tech supported by Xiangshang Yixin.

Email：uservice@ttm.financial

{"i18n":{"language":"en_US"},"data":{"magic":2,"id":898603416,"tweetId":"898603416","gmtCreate":1628489086435,"gmtModify":1703506939243,"author":{"id":3503452965237041,"authorId":3503452965237041,"authorIdStr":"3503452965237041","name":"美股研究社","avatar":"https://static.tigerbbs.com/a239c7906133df1f3817d0746a8a0ba1","vip":6,"userType":6,"introduction":"玩赚美股最好的资讯平台,你想要的美股行情、热点都在这里！","boolIsFan":false,"boolIsHead":false,"crmLevel":1,"crmLevelSwitch":0,"individualDisplayBadges":[],"fanSize":59320,"starInvestorFlag":false},"themes":[],"images":[{"img":"https://static.tigerbbs.com/f8da9b3c92a9ef23c3fa89e3c7edfa00","width":"533","height":"300"}],"coverImages":[{"img":"https://static.tigerbbs.com/f8da9b3c92a9ef23c3fa89e3c7edfa00","width":"533","height":"300"}],"title":"基於整體試驗最終數據下，印度批准強生新冠疫苗緊急使用授權","extraTitle":"","html":"<html><head></head><body><p>強生的單劑疫苗是繼阿斯利康(AZN.US)、Bharat Biotech、俄羅斯Gamaleya和Moderna(MRNA.US)之後在印度獲得監管授權的第五種新冠疫苗。</p><p class=\"t-img-caption\"><img src=\"https://static.tigerbbs.com/f8da9b3c92a9ef23c3fa89e3c7edfa00\" tg-width=\"533\" tg-height=\"300\"></p><p>美股研究社獲悉，據智通財經APP消息，印度衛生部部長Mansukh Mandaviya於上週六在其推特上表示，印度已批准<a target=\"_blank\" href=\"https://laohu8.com/S/JNJ\">$強生(JNJ)$</a>&nbsp;研發的新冠疫苗的緊急使用授權。</p><p>據悉，該批准是基於3期整體臨牀試驗的最終數據。強生已經與當地疫苗生產商Biological E Ltd簽署了供應協議，但具體的時間表尚未透露。</p><p>有媒體援引強生公司的聲明表示:“雖然我們期待着兌現我們的交付承諾，但現在透露交付疫苗的具體時間還爲時過早。”</p><p>據瞭解，在7月底，有媒體報道，強生的新冠疫苗對德爾塔變異病毒仍具有大約71%的有效性。</p><p>根據約翰霍普金斯大學的統計數據，印度的新冠病毒感染人數在全球排第二，但該國只有約8%的人口完成了全面疫苗接種。</p><p> 本文來源：美股研究社，旨在幫助中國投資者理解世界，專注報道美國科技股和中概股，對美股感興趣的朋友趕緊關注我們</p></body></html>","htmlText":"<html><head></head><body><p>強生的單劑疫苗是繼阿斯利康(AZN.US)、Bharat Biotech、俄羅斯Gamaleya和Moderna(MRNA.US)之後在印度獲得監管授權的第五種新冠疫苗。</p><p class=\"t-img-caption\"><img src=\"https://static.tigerbbs.com/f8da9b3c92a9ef23c3fa89e3c7edfa00\" tg-width=\"533\" tg-height=\"300\"></p><p>美股研究社獲悉，據智通財經APP消息，印度衛生部部長Mansukh Mandaviya於上週六在其推特上表示，印度已批准<a target=\"_blank\" href=\"https://laohu8.com/S/JNJ\">$強生(JNJ)$</a>&nbsp;研發的新冠疫苗的緊急使用授權。</p><p>據悉，該批准是基於3期整體臨牀試驗的最終數據。強生已經與當地疫苗生產商Biological E Ltd簽署了供應協議，但具體的時間表尚未透露。</p><p>有媒體援引強生公司的聲明表示:“雖然我們期待着兌現我們的交付承諾，但現在透露交付疫苗的具體時間還爲時過早。”</p><p>據瞭解，在7月底，有媒體報道，強生的新冠疫苗對德爾塔變異病毒仍具有大約71%的有效性。</p><p>根據約翰霍普金斯大學的統計數據，印度的新冠病毒感染人數在全球排第二，但該國只有約8%的人口完成了全面疫苗接種。</p><p> 本文來源：美股研究社，旨在幫助中國投資者理解世界，專注報道美國科技股和中概股，對美股感興趣的朋友趕緊關注我們</p></body></html>","text":"強生的單劑疫苗是繼阿斯利康(AZN.US)、Bharat Biotech、俄羅斯Gamaleya和Moderna(MRNA.US)之後在印度獲得監管授權的第五種新冠疫苗。 美股研究社獲悉，據智通財經APP消息，印度衛生部部長Mansukh Mandaviya於上週六在其推特上表示，印度已批准$強生(JNJ)$ 研發的新冠疫苗的緊急使用授權。 據悉，該批准是基於3期整體臨牀試驗的最終數據。強生已經與當地疫苗生產商Biological E Ltd簽署了供應協議，但具體的時間表尚未透露。 有媒體援引強生公司的聲明表示:“雖然我們期待着兌現我們的交付承諾，但現在透露交付疫苗的具體時間還爲時過早。” 據瞭解，在7月底，有媒體報道，強生的新冠疫苗對德爾塔變異病毒仍具有大約71%的有效性。 根據約翰霍普金斯大學的統計數據，印度的新冠病毒感染人數在全球排第二，但該國只有約8%的人口完成了全面疫苗接種。 本文來源：美股研究社，旨在幫助中國投資者理解世界，專注報道美國科技股和中概股，對美股感興趣的朋友趕緊關注我們","highlighted":1,"essential":1,"paper":2,"likeSize":8,"commentSize":5,"repostSize":1,"favoriteSize":0,"link":"https://ttm.financial/post/898603416","repostId":0,"isVote":1,"tweetType":1,"viewCount":1083,"commentLimit":10,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"symbols":["JNJ"],"verified":2,"subType":0,"readableState":1,"langContent":"CN","currentLanguage":"CN","warmUpFlag":false,"orderFlag":false,"shareable":true,"causeOfNotShareable":"","featuresForAnalytics":[],"commentAndTweetFlag":false,"upFlag":false,"length":765,"xxTargetLangEnum":"ZH_HK"},"commentList":[{"id":5470056,"gmtCreate":1628491019695,"gmtModify":1663232119137,"authorId":3570321585113621,"author":{"id":3570321585113621,"authorId":3570321585113621,"name":"nyf","avatar":"https://static.tigerbbs.com/50956299ccdc6503eb74b79565951e0c","vip":1,"hat":"https://static.tigerbbs.com/0a8758340a08196056f8bc1e54805193","crmLevel":4,"crmLevelSwitch":1,"individualDisplayBadges":[]},"repliedAuthorId":0,"objectId":898603416,"type":1,"supId":0,"prevId":0,"content":"Good","text":"Good","html":"Good","likeSize":1,"commentSize":0,"subComments":[],"verified":10,"allocateAmount":0,"commentType":"invalid","coins":0,"score":0},{"id":5469900,"gmtCreate":1628489872373,"gmtModify":1663232118250,"authorId":3582161778784599,"author":{"id":3582161778784599,"authorId":3582161778784599,"name":"Ivylow","avatar":"https://static.laohu8.com/default-avatar.jpg","vip":1,"crmLevel":2,"crmLevelSwitch":0,"individualDisplayBadges":[]},"repliedAuthorId":0,"objectId":898603416,"type":1,"supId":0,"prevId":0,"content":"?","text":"?","html":"?","likeSize":1,"commentSize":0,"subComments":[],"verified":10,"allocateAmount":0,"commentType":"invalid","coins":0,"score":0},{"id":5469937,"gmtCreate":1628490150875,"gmtModify":1663232117436,"authorId":3575171841320945,"author":{"id":3575171841320945,"authorId":3575171841320945,"name":"keithsk","avatar":"https://static.tigerbbs.com/014d1b6a0298e6edb4396623308e3416","vip":1,"currentWearingBadge":{"badgeId":"a83d7582f45846ffbccbce770ce65d84-1","templateUuid":"a83d7582f45846ffbccbce770ce65d84","name":"Real Trader","description":"Completed a transaction","bigImgUrl":"https://static.tigerbbs.com/2e08a1cc2087a1de93402c2c290fa65b","smallImgUrl":"https://static.tigerbbs.com/4504a6397ce1137932d56e5f4ce27166","grayImgUrl":"https://static.tigerbbs.com/4b22c79415b4cd6e3d8ebc4a0fa32604","redirectLinkEnabled":0,"hasAllocated":1,"isWearing":1,"stampPosition":0,"hasStamp":0,"allocationCount":1,"allocatedDate":"2021.12.21","individualDisplayEnabled":0,"individualDisplaySort":0,"categoryType":1100},"crmLevel":2,"crmLevelSwitch":0,"individualDisplayBadges":[]},"repliedAuthorId":0,"objectId":898603416,"type":1,"supId":0,"prevId":0,"content":"[Smile]","text":"[Smile]","html":"[Smile]","likeSize":1,"commentSize":0,"subComments":[],"verified":10,"allocateAmount":0,"commentType":"invalid","coins":0,"score":0},{"id":5469850,"gmtCreate":1628489502958,"gmtModify":1663232117427,"authorId":3568595506310108,"author":{"id":3568595506310108,"authorId":3568595506310108,"name":"Jacobkoo","avatar":"https://static.tigerbbs.com/633e4b5982ccd81476256a67dc38413b","vip":1,"crmLevel":3,"crmLevelSwitch":0,"individualDisplayBadges":[]},"repliedAuthorId":0,"objectId":898603416,"type":1,"supId":0,"prevId":0,"content":"<u>Good</u>","text":"<u>Good</u>","html":"<u>Good</u>","likeSize":2,"commentSize":0,"subComments":[],"verified":10,"allocateAmount":0,"commentType":"invalid","coins":0,"score":0},{"id":5469819,"gmtCreate":1628489226643,"gmtModify":1631896682699,"authorId":3579086889899920,"author":{"id":3579086889899920,"authorId":3579086889899920,"name":"Dino23","avatar":"https://static.tigerbbs.com/3022176fbd9f8d850b4dd8f580bbd030","vip":1,"crmLevel":7,"crmLevelSwitch":0,"individualDisplayBadges":[]},"repliedAuthorId":0,"objectId":898603416,"type":1,"supId":0,"prevId":0,"content":"?","text":"?","html":"?","likeSize":2,"commentSize":0,"subComments":[],"verified":10,"allocateAmount":0,"commentType":"invalid","coins":0,"score":0}],"hasMoreComment":true,"orderType":2}